DRREDDY
Dr. Reddy’s Laboratories Limited Receives Marketing Authorization for Generic Semaglutide Injection in Brazil
Dr. Reddy’s Laboratories Limited (DRREDDY) secures marketing authorization for generic semaglutide injection in Brazil, expanding its diabetes treatment opti.
Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) announced today that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for its generic semaglutide injection. This approval allows Dr. Reddy’s to offer the treatment for adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise. The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.
Significant Market Expansion
This authorization marks a significant step for Dr. Reddy’s in expanding its semaglutide presence to Brazil, one of the key markets in Latin America. Brazil has 16.6 million adults aged 20–79 living with diabetes, ranking sixth globally in terms of the number of adults living with diabetes. The semaglutide market for diabetes in Brazil is estimated at approximately USD 244.6 million.
Strategic Growth
Commenting on the approval, MV Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said, “Our focus with semaglutide is to expand access to this treatment option across markets where the patient need is significant. Brazil, with its substantial burden of diabetes, is an important part of that journey. This approval builds on our broader semaglutide strategy and brings us another step closer to making semaglutide available to more patients. We plan to launch semaglutide in Brazil with Aché.”
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, the company is committed to providing access to affordable and innovative medicines. Driven by its purpose of ‘Good Health Can’t Wait,’ Dr. Reddy’s offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, and OTC. The company’s major therapeutic areas of focus include gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. As a company with a history of deep science, Dr. Reddy’s continues to invest in businesses of the future and remains an early adopter of sustainability and ESG actions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited Q2fy27 Results Update: Double-digit Growth, Strong Financials
Dr. Reddy’s Laboratories Limited DRREDDY reports double-digit Q2FY27 growth, with ₹8,671 Cr revenue and 20.6% EBITDA margin.
Dr. Reddy’s Laboratories Limited (DRREDDY) showcased robust financial performance for Q2FY27, as per consolidated financial statements under IFRS. The company reported a revenue of ₹8,671 Cr, marking a 1.5% year-on-year growth. The EBITDA margin stood at 20.6%, reflecting consistent double-digit base business growth. The company’s progress across strategic priorities highlights its commitment to innovation and market expansion.
Financial Highlights
The financial highlights for Q2FY27 include a reported EBITDA of ₹1,783 Cr, a 24% year-on-year increase. The PBT reached ₹1,228 Cr, up 33% YoY, and PAT stood at ₹925 Cr, with a 36% YoY growth. Notably, the RoCE was annualized at 9.5%, and the net cash surplus stood at ₹2,502 Cr.
Strategic Initiatives
Dr. Reddy’s Laboratories Limited has made significant strides in its strategic initiatives. The company partnered with Takeda for India’s first CDSCO approved dengue vaccine, QDENGA, set to launch in private markets in H1 2027. Additionally, collaborations with Gilead Sciences and GARDP Foundation have expanded its global footprint.
The company also secured approval for rituximab biosimilar from the USFDA and launched nivolumab biosimilar in India. Furthermore, generic semaglutide has been approved in 10 countries across Latin America, Africa & the Middle East, as well as Canada & India.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (NSE: Drreddy) Receives DCGI Approval for Zytorvi® in Advanced Esophageal Squamous Cell Carcinoma
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced DCGI approval for Zytorvi® in advanced esophageal squamous cell carcinoma.
Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) announced today that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi® (toripalimab) in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This marks the second approved indication for Zytorvi® in India, expanding its use beyond its initial approval in nasopharyngeal carcinoma (NPC).
Expanding Access to Immunotherapy
Through this approval, Dr. Reddy’s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial, which demonstrated a 42% reduction in the risk of disease or death compared with chemotherapy alone.
Significant Market Opportunity
In 2024, esophageal cancer was the fourth leading cause of cancer-related death in India, accounting for approximately 8.1% of all cancer deaths. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. With this approval, Dr. Reddy’s Laboratories Ltd. is taking a significant step in addressing this critical need.
M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy’s Laboratories, said: “Following the approval of Zytorvi® in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first-line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. moves sideways over three months, with neither buyers nor sellers taking control. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 42% of its 52-week range with RSI at 58. In other words, neither side has a clear edge right now. Revenue grows at 11.0% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
DRREDDY
Dr. Reddy’s Laboratories Limited (drreddy) Q2fy27 Results: Earnings and Revenue Insights
Dr. Reddy’s Laboratories Limited (DRREDDY) to announce Q2FY27 results on October 23rd, focusing on earnings and revenue insights.
Dr. Reddy’s Laboratories Limited (DRREDDY) is set to release its financial results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd. The announcement will focus on key earnings and revenue insights. The company will hold an earnings call at 19:30 PM IST / 10:00 AM ET to discuss the financial performance. The call will be hosted by the company and can be accessed via the provided link for registration. This event marks a significant moment for investors and stakeholders to gain a deeper understanding of the company’s financial health and future prospects.
Financial Performance Overview
The upcoming release will provide detailed insights into Dr. Reddy’s Laboratories’ financial performance for Q2FY27. Notably, the company’s earnings and revenue are expected to reflect its strategic initiatives and market dynamics. The earnings call will offer a platform for management to elaborate on these aspects, highlighting key metrics and future growth strategies.
Investor Engagement
Investors are encouraged to participate in the earnings call to gain direct insights from the company’s leadership. The call will be available in audio format, with a transcript also accessible on the company’s website. This engagement is crucial for understanding the company’s current standing and future trajectory in the pharmaceutical sector.
As Dr. Reddy’s Laboratories Limited prepares to unveil its Q2FY27 results, the focus remains on delivering valuable financial insights that will guide stakeholders in making informed decisions.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited
Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Dr. falls 10.4% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -10.4% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Dr. Reddy’s Laboratories Limited.
-
AKUMS3 days agoAkums Drugs and Pharmaceuticals Limited (akums) Q2 FY27: Revenue Up 32%, Ebitda and PAT Surge
-
Information Technology Services3 days agoOrient Technologies Limited (orienttech) Q2 FY27: Strong Profitability on Higher Managed Services Contribution
-
Consumer Cyclical3 days agoTbo Tek Limited (tbotek) Q2 FY27: Revenue Up 53%, Adj. Ebitda at ₹152 Crores
-
Industrials3 days agoAmara Raja Energy & Mobility Limited (are&m) Q2 FY27: Revenue Up 13%
-
Auto Parts3 days agoJay Bharat Maruti Limited Q2 FY’27 Results: PAT Up 72.59%, Revenue Grows 41.97%
-
Basic Materials3 days agoJk Paper Limited (jkpaper) Q2 FY26: Consolidated Turnover Up 11%, PAT Rises 36%
-
Consumer Cyclical3 days agoSheela Foam Limited Q2 & H1 FY27 Results: Revenue Surpasses ₹1,000 Cr, PAT Up 6.6x Yoy
-
Apparel Retail3 days agoArvind Fashions Limited Announces Highest Ever Revenue and Ebitda, Delivers Revenue Growth of 10.0% and Ebitda Growth of 15.5%